Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

and Uptravi (selexipag), as well as a slew of pipeline products. And at the tail end of 2020, a $6.5 billion deal to buy Momenta meant that J&J added potential inflammatory disease blockbuster ...

J&J sells macitentan on its own as Opsumit, currently a top-selling drug for PAH with sales of $2 billion a year, and also makes $1.6 billion from prostacyclin analogue Uptravi (selexipag).

85 With riociguat, the concurrent use of PDE-5 inhibitors is not recommended. Selexipag is an orally available nonprostanoid diphenylpyrazine derivative and acts on the human prostaglandin I 2 (IP) ...

With appreciation for feedback from Mark Fendrick, Director of the Value-Based Insurance Design (V-BID) Center at the University of Michigan, and Daneen Seekoni, Vice President of Policy and ...

Le registre des drogues innovantes est tenu en vertu de l'article C.08.004.1(9) du Règlement sur les aliments et drogues. Le registre mentionne les drogues qui sont admissibles à la protection des ...

4 University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany Until recently, three classes of medical therapy were available for the ...

Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Rôle du sacubitril-valsartan dans la prévention de la cardiotoxicité chez les patients à haut risque traités par anthracyclines - Résultats du SARAH Trial ...